NASDAQ:APRI - Apricus Biosciences Stock Price, Forecast & News Notice: This company has been marked as potentially delisted and may not be actively trading. Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Apricus Biosciences Inc Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add Add Compare Today's Range N/A50-Day Range N/A52-Week Range N/AVolume673,266 shsAverage Volume558,386 shsMarket Capitalization$69.30 millionP/E RatioN/ADividend YieldN/ABeta1.2 ProfileAnalyst RatingsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email Apricus Biosciences, Inc, a biopharmaceutical company, focuses on the development of product candidates in the areas of urology and rheumatology. The company develops Vitaros, a topically-applied cream formulation of alprostadil used for the treatment of erectile dysfunction; and RayVa, which is in Phase IIa clinical trial to treat Raynaud's phenomenon associated with scleroderma. Read More… Industry, Sector and Symbol Stock Exchange NASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:APRI Previous Symbol CUSIPN/A CIK1017491 Webhttp://www.apricusbio.com/ Phone858-222-8041Debt Debt-to-Equity RatioN/A Current Ratio3.86 Quick Ratio3.86Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual Sales$5.76 million Price / Sales0.00 Cash FlowN/A Price / Cash FlowN/A Book Value$0.29 per share Price / BookN/AProfitability EPS (Most Recent Fiscal Year)($0.99) Net Income$320,000.00 Net MarginsN/A Return on Equity-216.45% Return on Assets-153.13%Miscellaneous EmployeesN/A Outstanding Shares28,170,000Market Cap$69.30 million Next Earnings DateN/A OptionableNot Optionable Receive APRI News and Ratings via Email Sign-up to receive the latest news and ratings for APRI and its competitors with MarketBeat's FREE daily newsletter. Apricus Biosciences (NASDAQ:APRI) Frequently Asked Questions What is Apricus Biosciences' stock symbol? Apricus Biosciences trades on the NASDAQ under the ticker symbol "APRI." How were Apricus Biosciences' earnings last quarter? Apricus Biosciences Inc (NASDAQ:APRI) posted its earnings results on Wednesday, October, 31st. The company reported ($0.12) earnings per share for the quarter, beating the Zacks' consensus estimate of ($0.14) by $0.02. View Apricus Biosciences' Earnings History. Has Apricus Biosciences been receiving favorable news coverage? Headlines about APRI stock have trended negative recently, according to InfoTrie Sentiment Analysis. The research firm identifies negative and positive press coverage by analyzing more than six thousand news and blog sources in real-time. The firm ranks coverage of companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Apricus Biosciences earned a news sentiment score of -2.8 on InfoTrie's scale. They also gave headlines about the company a news buzz of 0.0 out of 10, indicating that recent press coverage is extremely unlikely to have an impact on the stock's share price in the near term. View News Stories for Apricus Biosciences. Who are some of Apricus Biosciences' key competitors? Some companies that are related to Apricus Biosciences include Neptune Wellness Solutions (NEPT), Wave Life Sciences (WVE), VBI Vaccines (VBIV), Hookipa Pharma (HOOK), Sol Gel Technologies (SLGL), BIOFRONTERA AG/ADR (BFRA), Seres Therapeutics (MCRB), Evofem Biosciences (EVFM), MEI Pharma (MEIP), Kala Pharmaceuticals (KALA), Ocular Therapeutix (OCUL), Aeglea Bio Therapeutics (AGLE), Affimed (AFMD), Theratechnologies (THTX) and Theratechnologies (THERF). What other stocks do shareholders of Apricus Biosciences own? Based on aggregate information from My MarketBeat watchlists, some companies that other Apricus Biosciences investors own include Scotts Miracle-Gro (SMG), Pfizer (PFE), GrubHub (GRUB), Synergy Pharmaceuticals (SGYP), Boston Beer (SAM), Amicus Therapeutics (FOLD), Palatin Technologies (PTN), Novavax (NVAX), Rigel Pharmaceuticals (RIGL) and Chesapeake Energy (CHK). Who are Apricus Biosciences' key executives? Apricus Biosciences' management team includes the folowing people: Mr. Richard W. Pascoe, CEO, CFO, Sec., Principal Accounting Officer & Director (Age 55)Mr. Neil C. Morton, Sr. VP & Chief Bus. Officer (Age 43)Mr. Brian T. Dorsey, Consultant (Age 50)Ms. Kelly Deck, Exec. Director of Fin.Ms. Mary Naggs, VP & Gen. Counsel How big of a company is Apricus Biosciences? Apricus Biosciences has a market capitalization of $0.00 and generates $5.76 million in revenue each year. The company earns $320,000.00 in net income (profit) each year or ($0.99) on an earnings per share basis. View Additional Information About Apricus Biosciences. What is Apricus Biosciences' official website? The official website for Apricus Biosciences is http://www.apricusbio.com/. How can I contact Apricus Biosciences? Apricus Biosciences' mailing address is 11975 EL CAMINO REAL SUITE 300, SAN DIEGO CA, 92130. The company can be reached via phone at 858-222-8041 or via email at [email protected] MarketBeat Community Rating for Apricus Biosciences (NASDAQ APRI)Community Ranking: 2.7 out of 5 ( )Outperform Votes: 220 (Vote Outperform)Underperform Votes: 189 (Vote Underperform)Total Votes: 409MarketBeat's community ratings are surveys of what our community members think about Apricus Biosciences and other stocks. Vote "Outperform" if you believe APRI will outperform the S&P 500 over the long term. Vote "Underperform" if you believe APRI will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 1/24/2020 by MarketBeat.com StaffFeatured Article: What is the Dividend Aristocrat Index?